Overview

DC-CIK Immunotherapy Plus Chemotherapy vs Chemotherapy Alone in the Adjuvant Treatment of Stage III Colorectal Cancer

Status:
Unknown status

Trial end date:
2020-07-01

Target enrollment:

Participant gender:

Summary

Stage III colorectal cancer constitutes more than half of the colorectal patients, and the prognosis does not improve much recently although varies of adjuvant drugs have been tried. DC-CIK immunotherapy has been proved to improve survival in cancer patients, but its role in stage III colorectal cancer patients stains unclear. The investigators study will focus on the efficacy and safety of DC-CIK immunotherapy plus chemotherapy in the adjuvant treatment of stage III colorectal cancer, compared with chemotherapy alone.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Sixth Affiliated Hospital, Sun Yat-sen University

Treatments:

Fluorouracil
Leucovorin
Oxaliplatin